Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Nanologica AB's Enterprise Value for the quarter that ended in Jun. 2026 was €15.98 Mil.
Nanologica AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.25 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanologica AB EV-to-EBIT Related Terms
Nanologica AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Nanologica AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4YD vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, Nanologica AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanologica AB EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanologica AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Nanologica AB's EV-to-EBIT falls into.
Nanologica AB's current Enterprise Value is €12.37 Mil.
Nanologica AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.25 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanologica AB (FRA:4YD) has a EV-to-EBIT of 5.51 as of Sep. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Nanologica AB and its competitors. According to the industry distribution chart, Nanologica AB ranks #136 out of 381 companies in the Biotechnology industry, placing it in the top 35.7%.
Is Nanologica AB's EV-to-EBIT too high?
Nanologica AB's current EV-to-EBIT is 5.51. The Biotechnology industry median EV-to-EBIT is 14.08. Nanologica AB's value of 5.51 is 60.9% below this industry median. Based on the distribution chart, Nanologica AB ranks #136 out of 381 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nanologica AB has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Nanologica AB's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanologica AB ranks #136 out of 381 companies for EV-to-EBIT. This puts Nanologica AB in the upper half of its industry. The industry median EV-to-EBIT is 14.08. Nanologica AB's value of 5.51 is 60.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.08, based on 381 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanologica AB's current EV-to-EBIT of 5.51 is 60.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Nanologica AB and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanologica AB's current EV-to-EBIT is 5.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanologica AB stock overvalued right now?
Nanologica AB (FRA:4YD) has a current EV-to-EBIT of 5.51. The stock's GF Value™ is €0.18, compared to a current price of €0.02 — trading 89.9% below its estimated fair value. The current EV-to-EBIT is 5.51 and 60.9% below the Biotechnology industry median of 14.08. Nanologica AB's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Nanologica AB (FRA:4YD), the current EV-to-EBIT is 5.51 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanologica AB (FRA:4YD) Overvalued in 2026?
Based on GuruFocus' analysis, Nanologica AB stock appears to be undervalued.
The current stock price of €0.02 is trading 89.9% below its estimated GF Value™ of €0.18.
Key valuation signals for FRA:4YD:
EV-to-EBIT: 5.51
GF Value™: €0.18 vs. price of €0.02 (89.9% below fair value)
Industry Position: 60.9% below the Biotechnology median (#136 of 381)
No single metric tells the full story. See the FRA:4YD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells key consumables to pharmaceutical manufacturers. Its products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, it can increase productivity and reduce costs for pharmaceutical manufacturers. The group operates in a world-wide niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments.
46GF Score
Get the complete analysis for FRA:4YD
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4YD has been successfully added to your 
